[go: up one dir, main page]

MX2022012920A - Composiciones de resiniferatoxina. - Google Patents

Composiciones de resiniferatoxina.

Info

Publication number
MX2022012920A
MX2022012920A MX2022012920A MX2022012920A MX2022012920A MX 2022012920 A MX2022012920 A MX 2022012920A MX 2022012920 A MX2022012920 A MX 2022012920A MX 2022012920 A MX2022012920 A MX 2022012920A MX 2022012920 A MX2022012920 A MX 2022012920A
Authority
MX
Mexico
Prior art keywords
resiniferatoxin
compositions
liquid compositions
aqueous solid
aqueous
Prior art date
Application number
MX2022012920A
Other languages
English (en)
Inventor
Andreas BERNKOP-SCHNÜRCH
Olivier Valdenaire
Thomas Giller
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2022012920A publication Critical patent/MX2022012920A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La invención proporciona composiciones sólidas y líquidas no acuosas que comprenden resiniferatoxina y un tensoactivo. Las composiciones sólidas y líquidas no acuosas se pueden utilizar para preparar composiciones acuosas que se utilizan en el tratamiento del dolor, específicamente dolor articular relacionado con osteoartritis. Además, la invención proporciona kits que contienen las composiciones sólidas y líquidas no acuosas y un diluyente y métodos para preparar las composiciones. Las composiciones sólidas y líquidas no acuosas permiten un almacenamiento y recuperación más prolongados de resiniferatoxina en comparación con resiniferatoxina sola antes de la reconstitución con un diluyente.
MX2022012920A 2020-04-15 2021-04-13 Composiciones de resiniferatoxina. MX2022012920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169668 2020-04-15
PCT/EP2021/059562 WO2021209450A1 (en) 2020-04-15 2021-04-13 Resiniferatoxin compositions

Publications (1)

Publication Number Publication Date
MX2022012920A true MX2022012920A (es) 2022-11-16

Family

ID=70289711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012920A MX2022012920A (es) 2020-04-15 2021-04-13 Composiciones de resiniferatoxina.

Country Status (21)

Country Link
US (2) US20230051321A1 (es)
EP (2) EP4487872A3 (es)
JP (1) JP2023522537A (es)
KR (1) KR20230002560A (es)
CN (1) CN115551480B (es)
AU (1) AU2021256948B2 (es)
BR (1) BR112022020862A2 (es)
CA (1) CA3172784A1 (es)
DK (1) DK4135652T3 (es)
ES (1) ES3004508T3 (es)
FI (1) FI4135652T3 (es)
HR (1) HRP20250055T1 (es)
HU (1) HUE069859T2 (es)
IL (1) IL297063A (es)
LT (1) LT4135652T (es)
MX (1) MX2022012920A (es)
PL (1) PL4135652T3 (es)
PT (1) PT4135652T (es)
RS (1) RS66427B1 (es)
SI (1) SI4135652T1 (es)
WO (1) WO2021209450A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228815A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Lyophilized resiniferatoxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
EP2907503A1 (en) * 2003-04-10 2015-08-19 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
EP1838301B1 (de) * 2004-12-28 2015-01-28 Mestex AG Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen
CA2635581C (en) * 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
EA201890884A1 (ru) * 2015-10-06 2018-11-30 Флекс Фарма, Инк. Способ и композиции для нежелательных и аномальных мышечных сокращений
WO2017087803A1 (en) * 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
MX391441B (es) * 2016-08-02 2025-03-21 Durect Corp Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
JP2018024648A (ja) * 2016-08-05 2018-02-15 日本化薬株式会社 ボルテゾミブを含有する医薬製剤の製造方法
US20190321493A1 (en) * 2016-11-18 2019-10-24 Mayo Foundation For Medical Education And Research Materials and methods for treating regional pain
AU2018327301B2 (en) * 2017-09-11 2024-08-22 Vivasor, Inc. Formulation of resiniferatoxin
US12029725B2 (en) * 2019-01-22 2024-07-09 Vivasor, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin

Also Published As

Publication number Publication date
EP4135652B1 (en) 2024-12-18
JP2023522537A (ja) 2023-05-31
US20230051321A1 (en) 2023-02-16
FI4135652T3 (fi) 2025-01-21
SI4135652T1 (sl) 2025-03-31
EP4135652A1 (en) 2023-02-22
HRP20250055T1 (hr) 2025-03-28
WO2021209450A1 (en) 2021-10-21
BR112022020862A2 (pt) 2022-11-29
KR20230002560A (ko) 2023-01-05
LT4135652T (lt) 2025-02-10
CN115551480B (zh) 2025-11-18
ES3004508T3 (en) 2025-03-12
CA3172784A1 (en) 2021-10-21
HUE069859T2 (hu) 2025-04-28
RS66427B1 (sr) 2025-02-28
EP4487872A2 (en) 2025-01-08
CN115551480A (zh) 2022-12-30
US20240382449A1 (en) 2024-11-21
EP4487872A3 (en) 2025-03-26
AU2021256948A1 (en) 2022-09-01
DK4135652T3 (da) 2025-01-20
PT4135652T (pt) 2025-01-16
PL4135652T3 (pl) 2025-03-10
IL297063A (en) 2022-12-01
AU2021256948B2 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
AR107037A1 (es) Composiciones de emulsiones inversas
MX2018001531A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
MX2018007944A (es) Composiciones inoculantes estables y metodos para producirlas.
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CO2017009261A2 (es) Composiciones de dispersión de depresor del punto de vertido, acuosas, estables a solventes de hidrocarburos
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
BR112017012888A2 (pt) composição baseada em chlorella mixotrófica e processo para sua preparação e aplicação em plantas
MX2017013128A (es) Sistemas y metodos para reducir densidad de los datos en grandes conjuntos de datos.
BR112018009297A8 (pt) composição de limpeza e desinfecção
AR112957A1 (es) Proceso de limpieza de membrana
PE20171513A1 (es) Composicion acida a base de leonardita y aminoacidos
MX2017005576A (es) Aparatos y metodos para marcar viales o ampolletas almacenadas a temperaturas tan bajas como-200 °c.
MX2022012920A (es) Composiciones de resiniferatoxina.
PE20180334A1 (es) Sistemas y metodos para reducir las corrientes parasitas no deseadas
MX2017012457A (es) Un proceso para la preparacion de analogos alfa-hidroxilados de metionina a partir de azucares y derivados de los mismos.
SV2018005747A (es) Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas
MX2023009825A (es) Composicion y metodo de elaboracion de grasas a base de sulfonato utilizando un derivado de glicerol.
EA201691603A1 (ru) Производные сахаров, содержащие серосодержащие фрагменты, способы их получения и способы их применения для лечения mps iiic
UY35981A (es) Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol
EA201991585A1 (ru) Ксантановые структурированные жидкие очищающие средства с высоким содержанием многоатомных спиртов
FR2925917B1 (fr) Methode de conservation du sperme et ses applications.
AR107986A1 (es) Solubilización mejorada a través del uso de una combinación de surfactantes de cadena extendida
MX2016011406A (es) Composiciones polimericas y procesamiento de las mismas.
EA201991413A1 (ru) Вспомогательные вещества для составов на основе агрохимиката
UY36168A (es) FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH